share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

独家:SAB Biotherapeutics 告诉本辛加公司已成功完成针对 1 型糖尿病的新型免疫疗法 SAB-142 的 GLP 毒理学研究;Co.在大约 12 个月内提交 IND 申请
Benzinga Real-time News ·  2023/01/10 07:33

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Has Successfully Concluded IND-Enabling GLP Toxicology Study For SAB-142, A Novel Immunotherapeutic For Type 1 Diabetes; Co. To Submit IND Filing Within Approximately 12 Months

独家:SAB Biotherapeutics 告诉本辛加公司已成功完成针对 1 型糖尿病的新型免疫疗法 SAB-142 的 GLP 毒理学研究;Co.在大约 12 个月内提交 IND 申请

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发